Paris - Delayed Quote EUR

Acticor Biotech SAS (ALACT.PA)

0.3360 +0.0660 (+24.44%)
At close: April 26 at 5:35 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ALACT.PA

Recent News: ALACT.PA

View More
ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment

ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment
Business Wire 2 days ago
Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024

Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024
Business Wire 11 days ago
ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of March 31, 2024

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of March 31, 2024
Business Wire 21 days ago
ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of February 29, 2024

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of February 29, 2024
Business Wire last month
The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attacks

The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attacks
Business Wire 2 months ago

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack
GlobeNewswire 2 months ago
ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2024

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2024
Business Wire 2 months ago
Acticor Biotech Announces Its Financial Calendar for the 1st Half of 2024

Acticor Biotech Announces Its Financial Calendar for the 1st Half of 2024
Business Wire 2 months ago
ACTICOR BIOTECH: Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal

ACTICOR BIOTECH: Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal
Business Wire 3 months ago
ACTICOR BIOTECH: Half-Year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

ACTICOR BIOTECH: Half-Year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
Business Wire 3 months ago
ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of December 31, 2023

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of December 31, 2023
Business Wire 3 months ago
ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of November 30, 2023

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of November 30, 2023
Business Wire 4 months ago
View More

Related Tickers

ALNFL.PA NFL Biosciences SA
1.8200
-7.61%
 
POXEL.PA Poxel S.A.
0.6730
+1.97%
 
OSE.PA OSE Immunotherapeutics SA
5.56
-0.71%
 
VVY.AS Vivoryon Therapeutics N.V.
0.8000
-2.44%
 
ALINT.PA IntegraGen SA
0.5900
-1.67%
 
ALTME.PA TME Pharma N.V.
0.2490
+0.20%
 
LEXXW Lexaria Bioscience Corp.
0.7996
+12.62%
 
TNG.PA Transgene SA
1.2100
-5.47%
 
ATORX.ST Alligator Bioscience AB (publ)
0.9250
+1.09%
 
MDG1.DE Medigene AG
1.5050
-5.64%